大剂量重组人血管内皮抑素对肺癌转移瘤的实验研究*

目的　探讨大剂量重组人血管内皮抑素（恩度）单药对肺癌的作用。方法　建立肺癌裸鼠转移瘤模型，检测腹腔给药和皮下注射两种途径恩度（５０ｍｇ／ｋｇ）在实验ＳＤ大鼠中的血药浓度，同时分别设生理盐水对照组和恩度１０、２０、５０、１００、２００ｍｇ／（ｋｇ·ｄ）组，观察小鼠的生存情况，计算生存期以及肺部转移灶数量。结果　恩度腹腔给药和皮下注射两种途径药代动力学相似，半衰期约为２４ｈ。１００ｍｇ／（ｋｇ·ｄ）恩度组小鼠的中位生存期达６１天，较对照组延长１０天。小鼠肺部转移病灶数量与恩度剂量有一定相关性，１００ｍｇ／（ｋｇ·ｄ）恩度组转移灶数量最少，与对照组比较有统计学上显著差异（Ｐ＜０.０５）。结论　在肺癌转移瘤模型中，大剂量恩度能够有效地抑制肺癌的生长，生存期延长，生存质量较好。

Effects of recombinant human endostatin (endostar) on the growth of lung cancer metastasis

Objective This experiment was to identify the effect of recombinant human endostatin （endostar） on the growth of lung cancer in nude mouse. Methods A nude mouse mode with lung metastasis was established. Each group of mice was treated with high dose of endostar： 10mg/（kg·d） ,20mg/（kg·d） , 50mg/（kg·d） , 100mg/（kg·d）, 200mg/（kg·d） as well as a control group. Observe the living condition of the mice ; calculate survival time and number of metastasis on the lung. Results The median survival time of 100mg/（ kg·d）group was 61 days, which was lO days longer than the control group. Compared to the control group, a connection between the number of metastasis and dose was observed. The 100mg/（kg·d） group also has the least metastasis compared with control group（ P 〈 0. 05 ）. Conclusion High dose of endostar has the ability to inhibit the growth of lung cancer metastasis, is able to prolong the survival time.